All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BS01
Therapeutic Area: Ophthalmology Product Name: BS01
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
The patients began reporting observations about their perceptions 2-3 months after BS01 was injected, and then were tested objectively and quantitatively at a testing site at 3 month and 6 month time points.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2021
Details:
OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EXN407
Therapeutic Area: Ophthalmology Product Name: EXN407
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2021
Details:
In collaboration with Janssen Pharmaceuticals, the first patient has been dosed with Exonate's, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
